Development of Standardized Evaluation Methods for Novel Drug Delivery Systems in Cancer Therapy

Cancer remains a leading cause of morbidity and mortality worldwide despite advances in conventional therapies. Novel drug delivery systems (NDDS) offer promising strategies to enhance therapeutic efficacy and reduce systemic toxicity by targeted delivery of anticancer agents. However, the lack of standardized evaluation methods for these complex systems hampers reproducibility, regulatory approval, and clinical translation. This review focuses on current evaluation methodologies for NDDS in cancer therapy, highlights existing challenges, and proposes the development of standardized protocols to streamline preclinical and clinical assessments. Establishing universally accepted evaluation frameworks will accelerate the translation of innovative nanomedicines from bench to bedside.